OpenURL Connection Search

Select item for more details and to access through your institution.

Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series.
Published in:
Annals of Hematology, 2018, v. 97, n. 12, p. 2417, doi. 10.1007/s00277-018-3473-8
By:
- on behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group);
- Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group);
- Bobillo, S.;
- Abrisqueta, P.;
- Montoro, J.;
- López, A.;
- Bosch, F.;
- Bento, L.;
- Montes, S.;
- Sánchez-González, B.;
- Giné, E.;
- Romero, S.;
- Alcoceba, M.;
- González-Barca, E.;
- González de Villambrosía, S.;
- Sancho, J. M.;
- Gómez, P.
Publication type:
Article
ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S381, doi. 10.1016/S2152-2650(21)01868-1
By:
- Búa, Beatriz Rey;
- Ubieto, A Jiménez;
- Blanco, JJ Sánchez;
- Abrisqueta, P;
- Gutiérrez, A;
- Páyez, A Ramírez;
- Giné, E;
- Etxetxipia, I Zeberio;
- Terol, MJ;
- de la Cruz, F;
- Andreu, R.;
- Ramirez, MJ;
- de la Fuente, A;
- Viguria, MC;
- Peñarrubia, MJ;
- Grande, C.;
- Barrigón, MD Caballero;
- García-Sancho, A Martín
Publication type:
Article
Poster: ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S239, doi. 10.1016/S2152-2650(21)01500-7
By:
- Búa, Beatriz Rey;
- Ubieto, A. Jiménez;
- Blanco, JJ Sánchez;
- Abrisqueta, P.;
- Gutiérrez, A.;
- Páyez, A. Ramírez;
- Giné, E.;
- Etxetxipia, I. Zeberio;
- Terol, MJ;
- de la Cruz, F.;
- Andreu, R.;
- Ramirez, MJ;
- de la Fuente, A.;
- Viguria, MC;
- Peñarrubia, MJ;
- Grande, C.;
- Barrigón, MD Caballero;
- García-Sancho, A. Martín
Publication type:
Article
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Published in:
2014
By:
- Purroy, N;
- Abrisqueta, P;
- Carabia, J;
- Carpio, C;
- Calpe, E;
- Palacio, C;
- Castellví, J;
- Crespo, M;
- Bosch, F
Publication type:
journal article
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Published in:
Leukemia (08876924), 2014, v. 28, n. 10, p. 1993, doi. 10.1038/leu.2014.96
By:
- Purroy, N;
- Abrisqueta, P;
- Carabia, J;
- Carpio, C;
- Calpe, E;
- Palacio, C;
- Castellví, J;
- Crespo, M;
- Bosch, F
Publication type:
Article
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.
Published in:
Leukemia (08876924), 2013, v. 27, n. 5, p. 1100, doi. 10.1038/leu.2012.357
By:
- Villamor, N;
- Conde, L;
- Martínez-Trillos, A;
- Cazorla, M;
- Navarro, A;
- Beà, S;
- López, C;
- Colomer, D;
- Pinyol, M;
- Aymerich, M;
- Rozman, M;
- Abrisqueta, P;
- Baumann, T;
- Delgado, J;
- Giné, E;
- González-Díaz, M;
- Hernández, J M;
- Colado, E;
- Payer, A R;
- Rayon, C
Publication type:
Article
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.
Published in:
2013
By:
- Villamor, N;
- Conde, L;
- Martínez-Trillos, A;
- Cazorla, M;
- Navarro, A;
- Beà, S;
- López, C;
- Colomer, D;
- Pinyol, M;
- Aymerich, M;
- Rozman, M;
- Abrisqueta, P;
- Baumann, T;
- Delgado, J;
- Giné, E;
- González-Díaz, M;
- Hernández, J M;
- Colado, E;
- Payer, A R;
- Rayon, C
Publication type:
Journal Article
PHASE 1/2A CLINICAL TRIAL OF BI‐1206, A MONOCLONAL ANTIBODY TO CD32B (FCGRIIB), IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH INDOLENT B‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 835, doi. 10.1002/hon.3166_OT16
By:
- Jerkeman, M.;
- Costa, P. Abrisqueta;
- Hagberg, H. E.;
- Cia, J. M. Sancho;
- Bastos‐Oreiro, M.;
- Stevens, D.;
- Cohen, J. B;
- Mascunano, R. Cordoba;
- Domenech, E. Domingo;
- Román, I. Fernández;
- Canales, S. Novelli;
- Borggren, M.;
- Frendeus, B.;
- Karlsson, I.;
- Mårtensson, L.;
- Patel, S.;
- Teige, I.;
- Wallin, J. E.;
- Allister, A. Mc
Publication type:
Article
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
Published in:
Hematological Oncology, 2023, v. 41, p. 131, doi. 10.1002/hon.3163_88
By:
- Hertzberg, M.;
- Kalac, M.;
- Cheah, C. Y.;
- Ribrag, V.;
- Abrisqueta, P.;
- Opat, S.;
- Bachy, E.;
- Ysebaert, L.;
- Qiu, L.;
- Yi, S.;
- Nishimura, N.;
- Lemech, C.;
- Bussolari, J.;
- Deng, C.;
- Lu, T.;
- Xiu, L.;
- Hemelryck, S. V.;
- Philippar, U.;
- Guo, Y.;
- Soete, V.
Publication type:
Article
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS.
Published in:
Hematological Oncology, 2023, v. 41, p. 125, doi. 10.1002/hon.3163_84
By:
- Belada, D.;
- Falchi, L.;
- Leppä, S.;
- Vermaat, J. S.;
- Holte, H.;
- Hutchings, M.;
- Lugtenburg, P.;
- de Vos, S.;
- Abrisqueta, P.;
- Nijland, M.;
- Merryman, R. W.;
- Christensen, J. H.;
- Wahlin, B. E.;
- Linton, K. M.;
- Wang, L.;
- Abbas, A.;
- Rana, A.;
- Quadri, S.;
- Sureda, A.
Publication type:
Article
Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders.
Published in:
Hematological Oncology, 2023, v. 41, p. 607, doi. 10.1002/hon.3164_457
By:
- Serna, A.;
- Iraola‐Truchuelo, J.;
- Jiménez, M.;
- Cabirta, A.;
- Albasanz, A.;
- Ruiz‐Camps, I.;
- Andrés, C.;
- Antón, A.;
- Esperalba, J.;
- García, T.;
- Carpio, C.;
- Crespo, M.;
- Bobillo, S.;
- Iacoboni, G.;
- Marín‐Niebla, A.;
- Bosch, F.;
- Abrisqueta, P.
Publication type:
Article
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 439, doi. 10.1002/hon.3164_324
By:
- Duell, J.;
- Abrisqueta, P.;
- Dreyling, M.;
- Gaidano, G.;
- Barca, E. G.;
- Jurczak, W.;
- Maddocks, K. J.;
- Menne, T.;
- Nagy, Z.;
- Tournilhac, O.;
- Bakuli, A.;
- Amin, A.;
- Gurbanov, K.;
- Salles, G.
Publication type:
Article
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.
Published in:
Hematological Oncology, 2023, v. 41, p. 437, doi. 10.1002/hon.3164_323
By:
- Duell, J.;
- Abrisqueta, P.;
- Andre, M.;
- Augustin, M.;
- Gaidano, G.;
- Barca, E. G.;
- Jurczak, W.;
- Kalakonda, N.;
- Liberati, A. M.;
- Maddocks, K. J.;
- Menne, T.;
- Nagy, Z.;
- Tournilhac, O.;
- Bakuli, A.;
- Amin, A.;
- Gurbanov, K.;
- Salles, G.
Publication type:
Article
Novel therapies for the treatment of relapsed‐refractory aggressive B‐cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO group.
Published in:
Hematological Oncology, 2023, v. 41, p. 434, doi. 10.1002/hon.3164_320
By:
- Bastos‐Oreiro, M.;
- Abrisqueta, P.;
- Gutierrez, A.;
- Jimenez‐Ubieto, A.;
- Gonzalez de Villambrosia, S.;
- Córdoba, R.;
- López, A.;
- Poza, M.;
- Ceballos, E. Pérez;
- Navarro, B.;
- Muntañola, A.;
- Donato, E.;
- Escoda, L.;
- Luzardo, H.;
- Peñarrubia, M. J.;
- Pardal, E.;
- Belmonte, D. García;
- Lozada, C. Salazar;
- García‐Sancho, A. Martín
Publication type:
Article
Comparison Between aaIPI, LAB‐PI, NCCN‐IPI and GELTAMO‐IPI to Predict Prognosis in Elderly Patients with Diffuse Large‐B Cell Lymphoma who Undergo R‐CHOP/R‐miniCHOP.
Published in:
Hematological Oncology, 2023, v. 41, p. 413, doi. 10.1002/hon.3164_304
By:
- Martin‐Moro, F.;
- Marquet‐Palomanes, J.;
- Bento, L.;
- Diaz‐Lopez, A.;
- Garcia‐Vela, J. A.;
- Sanchez‐Pina, J. M;
- Cordoba, R.;
- Salar, A.;
- Novelli, S.;
- Rodriguez‐Salazar, M. J.;
- Lario‐Arribas, A.;
- Gonzalez, S.;
- Del Campo, R.;
- Luzardo, H. D.;
- Garcia, D.;
- Abrisqueta, P.;
- Garcia‐Sancho, A. Martin;
- Sancho, J. M.;
- Gutierrez, A.;
- Lopez‐Jimenez, F. J.
Publication type:
Article
Identification of biomarkers for predicting central nervous system involvement in patients with diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 296, doi. 10.1002/hon.3164_205
By:
- Pagès‐Geli, C.;
- Bobillo, S.;
- Abrisqueta, P.;
- Castellví, J.;
- Palomo, L.;
- Alvarez‐Errico, D.;
- Esteller, M.;
- Bosch, F.;
- Crespo, M.
Publication type:
Article
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial.
Published in:
Hematological Oncology, 2023, v. 41, p. 290, doi. 10.1002/hon.3164_200
By:
- Mozas, P.;
- Ammar, R. Ould;
- Chartier, L.;
- Nastoupil, L.;
- Bachy, E.;
- Bezsera, S. M.;
- Barnes, J.;
- Bijou, F.;
- Goy, A.;
- Zerazhi, H.;
- Cartron, G.;
- Ojeda‐Uribe, M.;
- Choquet, S.;
- Joly, B.;
- Cheminant, M.;
- García‐Sancho, A. Martín;
- Eradat, H.;
- Gressin, R.;
- Abrisqueta, P.;
- Parcelier, A.
Publication type:
Article
UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.94_2880
By:
- Búa, B. Rey;
- Jiménez‐Ubieto, A.;
- Blanco, J. J. Sánchez;
- Abrisqueta, P.;
- Gutiérrez, A.;
- Ramírez‐Páyer, Án.;
- Giné, E.;
- Etxetxipia, I. Zeberio;
- Terol, M. José;
- Cruz, F. de la;
- Andreu, R.;
- Ramírez, M.;
- Fuente, A. de la;
- Viguria, M.;
- Peñarrubia, M.;
- Grande, C.;
- Montes‐Moreno, S.;
- Barrigón, M. D. Caballero;
- García‐Sancho, A. Martín
Publication type:
Article
CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH R‐CHOP: STUDY OF THE SPANISH LYMPHOMA GROUP GELTAMO.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.91_2880
By:
- Franch‐Sarto, M.;
- Garcia‐Calduch, O.;
- Rivas, A.;
- Lopez, A.;
- Gonzalez‐Barca, E.;
- Sureda, A.;
- Baile, M.;
- Martin, A.;
- Salar, A.;
- Gutierrez, Antonio‐M.;
- Bastos, M.;
- Rodriguez, M.‐J.;
- Gonzalez, S.;
- Queizán, J.‐A.;
- Cordoba, R.;
- Montalbán, C.;
- Luzardo, H. D.;
- Abrisqueta, P.;
- Garcia, D.;
- Hong, A.
Publication type:
Article
CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH R‐CHOP: STUDY OF THE SPANISH LYMPHOMA GROUP GELTAMO.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.90_2880
By:
- Franch‐Sarto, M.;
- Garcia‐Calduch, O.;
- Rivas, A.;
- Lopez, A.;
- Gonzalez‐Barca, E.;
- Sureda, A.;
- Baile, M.;
- Martin, A.;
- Salar, A.;
- Gutierrez, Antonio‐M.;
- Bastos, M.;
- Rodriguez, M.‐J.;
- Gonzalez, S.;
- Queizán, J.‐A.;
- Cordoba, R.;
- Montalbán, C.;
- Luzardo, H. D.;
- Abrisqueta, P.;
- Garcia, D.;
- Hong, A.
Publication type:
Article
IBRUTINIB FOLLOWED BY OFATUMUMAB CONSOLIDATION IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): GELLC‐7 TRIAL FROM THE SPANISH GROUP OF CLL (GELLC)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.47_2880
By:
- Abrisqueta, P.;
- González‐Barca, E.;
- Ferrà, C.;
- Ríos, E.;
- Fernández de la Mata, M.;
- Delgado, J.;
- Andreu, R.;
- Án. Hernández‐Rivas, J.;
- José Terol, M.;
- González, M.;
- Belén Vidriales, M.;
- Baltasar, P.;
- De la Serna, J.;
- Ramírez Páyer, Án.;
- Ballester, C.;
- Moreno, C.;
- García‐Marco, J. A.;
- Córdoba, R.;
- Yáñez, L.;
- Casado, L. F.
Publication type:
Article
LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.28_2879
By:
- Duell, J;
- Maddocks, K. J;
- González‐Barca, E;
- Jurczak, W;
- Liberati, A. M;
- Obr, A;
- Gaidano, G;
- Abrisqueta, P;
- André, M;
- Dreyling, M;
- Menne, T;
- Dirnberger‐Hertweck, M.;
- Weirather, J;
- Ambarkhane, S;
- Salles, G
Publication type:
Article
POLATUZUMAB VEDOTIN + RITUXIMAB + LENALIDOMIDE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.155_2880
By:
- Diefenbach, C;
- Abrisqueta, P;
- Gonzalez-Barca, E;
- Panizo, C;
- Arguinano Perez, J. Maria;
- Miall, F;
- Bastos-Oreiro, M;
- Lopez-Guillermo, A;
- Banerjee, L;
- McMillan, A;
- Hirata, J;
- Musick, L;
- Saha, S;
- Croft, B;
- Seymour, E
Publication type:
Article
ANALYSIS OF CIRCULATING TUMOR DNA (ctDNA) IN CEREBROSPINAL FLUID DETECTS THE PRESENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN B‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2019, v. 37, p. 188, doi. 10.1002/hon.3_2630
By:
- Bobillo, S.;
- Crespo, M.;
- Escudero, L.;
- Mayor, R.;
- Raheja, P.;
- Abrisqueta, P.;
- Palacio‐Garcia, C.;
- Montoro, J.;
- Jimenez, I.;
- Nieto, J.C.;
- Carabia, J.;
- Martinez‐Ricarte, F.;
- Castellvi, J.;
- Puigdefabregas, L.;
- Bosch, F.;
- Seoane, J.
Publication type:
Article
A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.
Published in:
Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
By:
- Zelenetz, A.;
- Zinzani, P.;
- Buske, C.;
- Ribrag, V.;
- Cunningham, D.;
- Jurczak, W.;
- Abrisqueta, P.;
- Agajanian, R.;
- Chaudhry, A.;
- Kayyal, T.;
- Wood, J.;
- Llorin‐Sangalang, J.;
- Brown, J.
Publication type:
Article
POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS.
Published in:
Hematological Oncology, 2019, v. 37, p. 175, doi. 10.1002/hon.132_2629
By:
- Diefenbach, C.;
- Kahl, B.;
- Banerjee, L.;
- McMillan, A.;
- Ramchandren, R.;
- Miall, F.;
- Briones, J.;
- Cordoba, R.;
- Gonzalez‐Barca, E.;
- Panizo, C.;
- Hirata, J.;
- Chang, N.;
- Musick, L.;
- Abrisqueta, P.
Publication type:
Article
REVERSAL OF IMMUNE TOLERANCE AND INCREASED SURVIVAL AFTER XPO1 AND BTK INHIBITION IN MOUSE MODELS OF PRIMARY CNS LYMPHOMA (PCNSL).
Published in:
Hematological Oncology, 2019, v. 37, p. 321, doi. 10.1002/hon.131_2630
By:
- Jiménez, I.;
- Carabia, J.;
- Bobillo, S.;
- Palacio, C.;
- Abrisqueta, P.;
- Nieto, J.C.;
- Castellví, J.;
- Martínez‐Ricarte, F.;
- Escoda, L.;
- Perla, C.;
- Cespedes, D.H.;
- Boix, J.;
- Purroy, N.;
- Puigdefàbregas, L.;
- Seoane, J.;
- Bosch, F.;
- Crespo, M.
Publication type:
Article
ANALYSIS OF CIRCULATING TUMOR DNA (ctDNA) IN CEREBROSPINAL FLUID DETECTS THE PRESENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN B‐CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2019, v. 37, p. 188, doi. 10.1002/hon.3_2630
By:
- Bobillo, S.;
- Crespo, M.;
- Escudero, L.;
- Mayor, R.;
- Raheja, P.;
- Abrisqueta, P.;
- Palacio‐Garcia, C.;
- Montoro, J.;
- Jimenez, I.;
- Nieto, J.C.;
- Carabia, J.;
- Martinez‐Ricarte, F.;
- Castellvi, J.;
- Puigdefabregas, L.;
- Bosch, F.;
- Seoane, J.
Publication type:
Article
A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.
Published in:
Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
By:
- Zelenetz, A.;
- Zinzani, P.;
- Buske, C.;
- Ribrag, V.;
- Cunningham, D.;
- Jurczak, W.;
- Abrisqueta, P.;
- Agajanian, R.;
- Chaudhry, A.;
- Kayyal, T.;
- Wood, J.;
- Llorin‐Sangalang, J.;
- Brown, J.
Publication type:
Article
POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS.
Published in:
Hematological Oncology, 2019, v. 37, p. 175, doi. 10.1002/hon.132_2629
By:
- Diefenbach, C.;
- Kahl, B.;
- Banerjee, L.;
- McMillan, A.;
- Ramchandren, R.;
- Miall, F.;
- Briones, J.;
- Cordoba, R.;
- Gonzalez‐Barca, E.;
- Panizo, C.;
- Hirata, J.;
- Chang, N.;
- Musick, L.;
- Abrisqueta, P.
Publication type:
Article
REVERSAL OF IMMUNE TOLERANCE AND INCREASED SURVIVAL AFTER XPO1 AND BTK INHIBITION IN MOUSE MODELS OF PRIMARY CNS LYMPHOMA (PCNSL).
Published in:
Hematological Oncology, 2019, v. 37, p. 321, doi. 10.1002/hon.131_2630
By:
- Jiménez, I.;
- Carabia, J.;
- Bobillo, S.;
- Palacio, C.;
- Abrisqueta, P.;
- Nieto, J.C.;
- Castellví, J.;
- Martínez‐Ricarte, F.;
- Escoda, L.;
- Perla, C.;
- Cespedes, D.H.;
- Boix, J.;
- Purroy, N.;
- Puigdefàbregas, L.;
- Seoane, J.;
- Bosch, F.;
- Crespo, M.
Publication type:
Article
APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS.
Published in:
Hematological Oncology, 2017, v. 35, p. 156, doi. 10.1002/hon.2438_11
By:
- Baptista, M.;
- Tapia, G.;
- Muñoz ‐ Marmol, A.;
- Muncunill, J.;
- Montoto, S.;
- Gribben, J.;
- Calaminici, M.;
- Martinez, A.;
- Gonzalez ‐ Farre, B.;
- López ‐ Guillermo, A.;
- González ‐ Barca, E.;
- Terol, M.;
- Miralles, P.;
- Alcoceba, M.;
- Vall ‐ Llovera, F.;
- Briones, J.;
- Abrisqueta, P.;
- Abella, E.;
- Provencio, M.;
- García ‐ Ballesteros, C.
Publication type:
Article
Post-transplant monomorphic Burkitt's lymphoma: Clinical characteristics and outcome of a multicenter series.
Published in:
Hematological Oncology, 2017, v. 35, p. 349, doi. 10.1002/hon.2439_100
By:
- Bobillo, S.;
- Abrisqueta, P.;
- Sánchez ‐ González, B.;
- Giné, E.;
- Romero, S.;
- Alcoceba, M.;
- González ‐ Barca, E.;
- González de Villambrosía, S.;
- Sancho, J.M.;
- Castellví, J.;
- López, A.;
- Bosch, F.
Publication type:
Article

Found: 33